A few years ago the Bill & Melinda Gates Foundation started topping up its grant-giving activities by investing directly in companies that may be able to help fulfil its mission. Now, it allocates US$1.5 billion to start-up funding, loans, purchase agreements and other programme-related investments (PRIs), bolstering the global health sector and research into HIV, malaria, tuberculosis (TB) and neglected tropical diseases. Bob More, who previously worked at Frazier Healthcare and at Domain Associates financing nascent biotech firms, oversees the venture capital component of these investments. After one year on the job, he tells Asher Mullard that finding alignment between charitable backers and financially driven entrepreneurs and investors is the key to successful philanthropic venture capitalism.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Bob More. Nat Rev Drug Discov 13, 648 (2014). https://doi.org/10.1038/nrd4421
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd4421
